Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 57

1.

Therapeutic Strategies for Treatment of Pulmonary Lymphangioleiomyomatosis (LAM).

Krymskaya VP.

Expert Opin Orphan Drugs. 2014 Oct 1;2(10):1063-1074. Epub 2014 Aug 27.

2.

Expression of Beclin Family Proteins Is Associated with Tumor Progression in Oral Cancer.

Liu JL, Chen FF, Chang SF, Chen CN, Lung J, Lo CH, Lee FH, Lu YC, Hung CH.

PLoS One. 2015 Oct 27;10(10):e0141308. doi: 10.1371/journal.pone.0141308. eCollection 2015.

3.

PAK2 is an effector of TSC1/2 signaling independent of mTOR and a potential therapeutic target for Tuberous Sclerosis Complex.

Alves MM, Fuhler GM, Queiroz KC, Scholma J, Goorden S, Anink J, Spek CA, Hoogeveen-Westerveld M, Bruno MJ, Nellist M, Elgersma Y, Aronica E, Peppelenbosch MP.

Sci Rep. 2015 Sep 28;5:14534. doi: 10.1038/srep14534.

4.

Cross-cancer profiling of molecular alterations within the human autophagy interaction network.

Lebovitz CB, Robertson AG, Goya R, Jones SJ, Morin RD, Marra MA, Gorski SM.

Autophagy. 2015;11(9):1668-87. doi: 10.1080/15548627.2015.1067362.

5.

Beclin orthologs: integrative hubs of cell signaling, membrane trafficking, and physiology.

Levine B, Liu R, Dong X, Zhong Q.

Trends Cell Biol. 2015 Sep;25(9):533-44. doi: 10.1016/j.tcb.2015.05.004. Epub 2015 Jun 11. Review.

PMID:
26071895
6.

A REDD1/TXNIP pro-oxidant complex regulates ATG4B activity to control stress-induced autophagy and sustain exercise capacity.

Qiao S, Dennis M, Song X, Vadysirisack DD, Salunke D, Nash Z, Yang Z, Liesa M, Yoshioka J, Matsuzawa S, Shirihai OS, Lee RT, Reed JC, Ellisen LW.

Nat Commun. 2015 Apr 28;6:7014. doi: 10.1038/ncomms8014.

7.

Multiple myeloma acquires resistance to EGFR inhibitor via induction of pentose phosphate pathway.

Chen Y, Huang R, Ding J, Ji D, Song B, Yuan L, Chang H, Chen G.

Sci Rep. 2015 Apr 20;5:9925. doi: 10.1038/srep09925.

8.

Effects of combining rapamycin and resveratrol on apoptosis and growth of TSC2-deficient xenograft tumors.

Alayev A, Salamon RS, Sun Y, Schwartz NS, Li C, Yu JJ, Holz MK.

Am J Respir Cell Mol Biol. 2015 Nov;53(5):637-46. doi: 10.1165/rcmb.2015-0022OC.

PMID:
25844891
9.

Autophagy in malignant transformation and cancer progression.

Galluzzi L, Pietrocola F, Bravo-San Pedro JM, Amaravadi RK, Baehrecke EH, Cecconi F, Codogno P, Debnath J, Gewirtz DA, Karantza V, Kimmelman A, Kumar S, Levine B, Maiuri MC, Martin SJ, Penninger J, Piacentini M, Rubinsztein DC, Simon HU, Simonsen A, Thorburn AM, Velasco G, Ryan KM, Kroemer G.

EMBO J. 2015 Apr 1;34(7):856-80. doi: 10.15252/embj.201490784. Epub 2015 Feb 23. Review.

10.

mTOR: a pharmacologic target for autophagy regulation.

Kim YC, Guan KL.

J Clin Invest. 2015 Jan;125(1):25-32. doi: 10.1172/JCI73939. Epub 2015 Jan 2. Review.

11.

Management of lymphangioleiomyomatosis.

Taveira-DaSilva AM, Moss J.

F1000Prime Rep. 2014 Dec 1;6:116. doi: 10.12703/P6-116. eCollection 2014. Review.

12.
13.

The neural crest lineage as a driver of disease heterogeneity in Tuberous Sclerosis Complex and Lymphangioleiomyomatosis.

Delaney SP, Julian LM, Stanford WL.

Front Cell Dev Biol. 2014 Nov 25;2:69. doi: 10.3389/fcell.2014.00069. eCollection 2014. Review.

14.

RNA-Seq and ChIP-Seq reveal SQSTM1/p62 as a key mediator of JunB suppression of NF-κB-dependent inflammation.

Zhang X, Jin JY, Wu J, Qin X, Streilein R, Hall RP, Zhang JY.

J Invest Dermatol. 2015 Apr;135(4):1016-24. doi: 10.1038/jid.2014.519. Epub 2014 Dec 16.

15.

Targeted deletion of Tsc1 causes fatal cardiomyocyte hyperplasia independently of afterload.

Kayyali US, Larsen CG, Bashiruddin S, Lewandowski SL, Trivedi CM, Warburton RR, Parkhitko AA, Morrison TA, Henske EP, Chekaluk Y, Kwiatkowski DJ, Finlay GA.

Cardiovasc Pathol. 2015 Mar-Apr;24(2):80-93. doi: 10.1016/j.carpath.2014.10.005. Epub 2014 Nov 7.

16.

Therapeutic targeting of cellular metabolism in cells with hyperactive mTORC1: a paradigm shift.

Medvetz D, Priolo C, Henske EP.

Mol Cancer Res. 2015 Jan;13(1):3-8. doi: 10.1158/1541-7786.MCR-14-0343. Epub 2014 Oct 8. Review.

17.

Regulation of YAP by mTOR and autophagy reveals a therapeutic target of tuberous sclerosis complex.

Liang N, Zhang C, Dill P, Panasyuk G, Pion D, Koka V, Gallazzini M, Olson EN, Lam H, Henske EP, Dong Z, Apte U, Pallet N, Johnson RL, Terzi F, Kwiatkowski DJ, Scoazec JY, Martignoni G, Pende M.

J Exp Med. 2014 Oct 20;211(11):2249-63. doi: 10.1084/jem.20140341. Epub 2014 Oct 6.

18.

High-throughput drug screen identifies chelerythrine as a selective inducer of death in a TSC2-null setting.

Medvetz D, Sun Y, Li C, Khabibullin D, Balan M, Parkhitko A, Priolo C, Asara JM, Pal S, Yu J, Henske EP.

Mol Cancer Res. 2015 Jan;13(1):50-62. doi: 10.1158/1541-7786.MCR-14-0440. Epub 2014 Sep 3.

19.

Mitophagy promotes replication of oncolytic Newcastle disease virus by blocking intrinsic apoptosis in lung cancer cells.

Meng G, Xia M, Wang D, Chen A, Wang Y, Wang H, Yu D, Wei J.

Oncotarget. 2014 Aug 15;5(15):6365-74.

20.

Rapamycin-resistant poly (ADP-ribose) polymerase-1 overexpression is a potential therapeutic target in lymphangioleiomyomatosis.

Sun Y, Gallacchi D, Zhang EY, Reynolds SB, Robinson L, Malinowska IA, Chiou TT, Pereira AM, Li C, Kwiatkowski DJ, Lee PS, Yu JJ.

Am J Respir Cell Mol Biol. 2014 Dec;51(6):738-49. doi: 10.1165/rcmb.2014-0033OC.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk